Learn More About QuadraSphere® Microspheres
Features & Benefits
Predictable, Flow-Directed Targeting
QuadraSphere® Microspheres are calibrated, hydrophilic and compress up to 80% to facilitate smooth microcatheter delivery. Once through the microcatheter, they rebound to their stated spherical shape with a consistent cross-sectional diameter for predictable, flow-directed targeting.
The in vivo median diameter of occluded arteries is significantly different between sizes of QuadraSphere Microspheres,* providing targeted occlusion.
QuadraSphere Q2 Microspheres demonstrate a median occlusion of 78 µm, a statistically significant difference compared to larger sizes of QuadraSphere.
*Swine liver embolization model study performed for Merit Medical. QuadraSphere Microspheres prepared in 50/50 mixture of saline/contrast.
Angiographies of hypervascularized tumor pre- and post-embolization illustrate the ability of QuadraSphere Microspheres to perform a targeted embolization.
Experience the Power of Conformability
QuadraSphere Microspheres are soft and easily conform to the vessel lumen for complete occlusion:
- Decreasing the risk of vessel recanalization1
- Enabling greater tumor necrosis2,3
- Providing optimal contact between the vessel wall and microsphere surface1,4
- Enhancing the embolic effect, reducing the amount of product needed to reach embolization endpoint1
QuadraSphere Microspheres are a recognized and accepted platform for targeted liver embolization. QuadraSphere Microspheres are indicated for:
- Arteriovenous Malformations (AVM)
- Hypervascular Tumors (HVT)
Referred to as super-absorbent polymer (SAP) microspheres, QuadraSphere Microspheres are packaged dry, but once exposed to aqueous-based media, they swell to approximately 4x the size printed on the product label.
- Bilbao JI, de Luis E, Garcia de Jalón JA, et al. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. J Vasc Interv Radiol 2008 Nov;19(11):1625-38.
- Lee KH, Liapi E, Vossen JA, et al. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol 2008 Oct;19(10);1490-6.
- Wáng YXJ, De Baere, Idée JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27(2):96-121
- Van Malenstein H, Maleux G, Vandecaveye V, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011;34(7):368-76.
|Catalog Number||Expanded Family Name||Size Range||Expanding Range||Delivery System||Delivery System Size||Color||Carrier Solution||Volume||HCPCS Code|
|V125QS||QuadraSphere® Microspheres||20-40 µm||80-160 µm||Vial||10 mL||Gray||Dry||25 mg|
|V225QS||QuadraSphere® Microspheres||30-60 µm||120-240 µm||Vial||10 mL||Orange||Dry||25 mg||No Applicable Code|
|V325QS||QuadraSphere® Microspheres||50-100 µm||200-400 µm||Vial||10 mL||Light Green||Dry||25 mg||No Applicable Code|
|V525QS||QuadraSphere® Microspheres||100-150 µm||400-600 µm||Vial||10 mL||Blue||Dry||25 mg||No Applicable Code|
|V725QS||QuadraSphere® Microspheres||150-200 µm||600-800 µm||Vial||10 mL||Purple||Dry||25 mg||No Applicable Code|